CagriSema’s Lowest Dose Matched Its Middle One. The Peer-Reviewed Paper Fills In the Gaps

Share

When Novo Nordisk first announced topline results from REDEFINE 9 in September, it highlighted one number: people taking the lowest tested dose of CagriSema lost an estimated 21 percent of their body weight. Grey Pepper noted at the time that the release left gaps, including full results for the second dose arm and details about how many people stayed on treatment. The peer-reviewed paper, published online in The Lancet Diabetes & Endocrinology on November 14, fills several of them.

The results are striking. CagriSema at 1.0 mg of each component produced an estimated 21.0 percent weight reduction after 68 weeks, while 1.7 mg of each produced 20.7 percent using the trial’s efficacy estimand. The two results were remarkably close, despite the difference in dose. But other analyses tell a more complicated story, and the trial was not designed to establish whether one active dose was equivalent or superior to the other.

This is human clinical evidence from a randomized, placebo-controlled, phase 3b trial funded by Novo Nordisk. It is also evidence about an investigational medicine, not one currently approved for clinical use in the United States.

CagriSema is a once-weekly injection combining cagrilintide, a long-acting analogue of the pancreatic hormone amylin, with semaglutide, the GLP-1 receptor agonist used in Wegovy. Novo submitted the full-dose combination, containing 2.4 mg of each component, to the FDA in December 2025 and continues to expect a decision during the fourth quarter of 2026.

The logic behind the combination is that amylin and GLP-1 act through different, partly complementary biological pathways. Amylin is normally released alongside insulin after meals and participates in signals that reduce food intake and regulate gastric emptying. GLP-1 receptor agonists also affect appetite, satiety and blood glucose regulation. Combining the two could produce more weight loss than either pathway alone.

That raises an obvious question: how much of each drug is actually needed? The same question is relevant to other investigational amylin treatments, including petrelintide, whose development program Grey Pepper has examined. Across the field, researchers are trying to understand how to balance efficacy, tolerability and sustainable treatment.

What REDEFINE 9 tested

REDEFINE 9 was a phase 3b clinical trial conducted at 24 sites in Canada, France, Germany, the United Kingdom and the United States. It enrolled 309 adults without diabetes who had obesity, defined as a body mass index of at least 30, or overweight with a BMI of at least 27 and at least one obesity-related complication.

Participants were randomized to once-weekly CagriSema containing either 1.7 mg of cagrilintide plus 1.7 mg of semaglutide, or 1.0 mg of each component, or a matching placebo regimen. The trial included 104 participants assigned to the 1.7 mg combination, 103 assigned to the 1.0 mg combination and 102 assigned to placebo groups pooled for analysis.

Participants and investigators were masked to active treatment or placebo within each dose level. The design was not a conventional head-to-head trial intended to establish which active dose performed better. Each dose was principally evaluated against its corresponding placebo comparison.

Treatment lasted 68 weeks and was accompanied by nutrition and physical-activity counseling. The 1.0 mg combination was escalated over eight weeks, while the 1.7 mg regimen was escalated over twelve weeks. Participants began with a lower introductory dose before progressing toward their assigned maintenance regimen.

The average participant was approximately 48 years old, with a baseline BMI of about 39.1. The study population therefore included adults with substantial excess body weight rather than people seeking minor cosmetic weight loss.

The CagriSema results, dose by dose

The trial’s efficacy estimand estimates the treatment effect under a scenario in which participants adhered to their assigned treatment. Under that analysis, mean body weight fell by an estimated 20.7 percent with CagriSema 1.7 mg of each component and 21.0 percent with CagriSema 1.0 mg of each, compared with 2.0 percent in the pooled placebo group.

The estimated treatment differences versus placebo were 18.8 percentage points for the 1.7 mg regimen and 19.0 percentage points for the 1.0 mg regimen. Both differences were statistically significant, with p values below 0.0001.

The proportions of participants estimated to achieve at least 5 percent weight reduction were also high: 95.1 percent with 1.7 mg of each component, 96.3 percent with 1.0 mg of each, and 33.4 percent on placebo.

At the more demanding threshold of at least 20 percent weight loss, the estimated proportions were 51.3 percent, 48.3 percent and 2.7 percent, respectively. Both active regimens therefore produced substantial reductions in body weight across multiple measures.

The lowest tested dose did not meaningfully separate from the middle dose in the primary efficacy estimates. Whether the two are truly equivalent remains unproven.

The most interesting result is that the 1.0 mg combination was numerically ahead of the 1.7 mg combination by just 0.3 percentage points under the efficacy estimand. That is a small difference relative to the uncertainty around each estimate. It should not be interpreted as evidence that the lower dose is more effective.

REDEFINE 9 was not designed or statistically powered to compare the two active doses directly. It cannot establish equivalence, noninferiority or superiority between them. The finding does, however, challenge the assumption that more drug must always produce substantially more average weight loss.

The second analysis changes the picture slightly

The peer-reviewed publication and accompanying November 14 results release also provide a second way to interpret the trial: the treatment-regimen estimand. Unlike the efficacy estimand, this analysis evaluates outcomes regardless of whether participants discontinued treatment or used a permitted weight-management rescue intervention.

Under this analysis, estimated mean weight loss was 19.4 percent with CagriSema 1.7 mg of each component, 18.6 percent with 1.0 mg of each, and 4.6 percent with pooled placebo.

Here, the numerical order of the active treatments reversed. The 1.7 mg regimen was ahead by 0.8 percentage points, although the study was again not designed to establish a meaningful difference between active doses. Both remained statistically superior to placebo, with estimated treatment differences of 14.7 and 13.9 percentage points, respectively.

This distinction matters because the efficacy and treatment-regimen estimands answer different questions. One models weight reduction under continued adherence; the other incorporates the consequences of treatment discontinuation and rescue intervention into the estimated overall result.

Neither estimate should automatically be treated as the precise weight loss an individual patient can expect. Clinical trial averages describe groups, and real-world results depend on individual response, treatment continuation, medical history and other factors.

The two analyses do, however, reinforce the central finding: meaningful weight reduction occurred with both CagriSema dose levels well below the 2.4 mg combination submitted to the FDA.

Who stayed on, and who had side effects

The paper also provides information about treatment continuation that was missing from the September topline announcement. Of the 309 randomized participants, 291, or 94 percent, completed the trial. At week 68, 254 participants, or 82 percent, were still on treatment.

Those figures should not be confused. Completing the study means that a participant remained in follow-up through the relevant endpoint, while remaining on treatment means that the participant was still receiving the assigned regimen at week 68.

Adverse events were reported by 99 percent of participants assigned to CagriSema 1.7 mg of each component, 95 percent assigned to 1.0 mg of each, and 91 percent assigned to placebo. Most events were mild or moderate in severity, and gastrointestinal complaints were the most frequent.

Nausea was reported in approximately 66 percent of participants receiving the 1.7 mg combination and 62 percent receiving 1.0 mg, compared with 26 percent on placebo. Constipation was reported in 48 percent, 37 percent and 21 percent, respectively. Vomiting occurred in 32 percent, 27 percent and 7 percent.

Serious adverse events were reported in 15 percent of the 1.7 mg group, 13 percent of the 1.0 mg group and 12 percent of the pooled placebo group. No deaths were reported in the trial.

Adverse events leading to permanent treatment discontinuation occurred in 2.9 percent of participants receiving 1.7 mg of each component, 4.9 percent receiving 1.0 mg of each, and 4.9 percent receiving placebo. These percentages are small, but the numerical pattern does not support a simple claim that the lowest dose caused fewer treatment discontinuations.

The gastrointestinal event rates were generally numerically lower with the 1.0 mg regimen than with the 1.7 mg regimen, but the study was not powered to establish a direct tolerability advantage between them. Longer and larger comparisons would be needed to determine whether a particular dose meaningfully improves persistence or tolerability.

A lower dose is attractive if it preserves efficacy and improves tolerability. REDEFINE 9 supports the efficacy argument but does not settle the tolerability comparison.

How this fits the bigger CagriSema story

CagriSema’s pivotal REDEFINE 1 trial reported estimated weight loss of 22.7 percent with the 2.4 mg combination under an efficacy-style, trial-product estimand, and 20.4 percent under the treatment-policy estimand. These were substantial results, but investors had expected more. Novo Nordisk’s shares fell sharply after the December 2024 announcement.

One detail became particularly important. The REDEFINE 1 protocol allowed flexible dosing, and only 57.3 percent of participants assigned to CagriSema were receiving the highest dose at week 68. That raised questions about dose escalation, tolerability, and how the trial’s results should be interpreted.

The issue subsequently became part of a shareholder lawsuit. In July 2026, a federal judge allowed portions of the case against Novo Nordisk to proceed, according to Reuters. That ruling allowed certain investor allegations to continue in litigation; it was not a finding that the allegations had been proved.

Grey Pepper previously examined the relationship between the lawsuit and the lower-dose study in its reporting ahead of REDEFINE 9’s detailed release. The new paper now provides a clearer view of what the lower-dose regimens achieved and how participants tolerated treatment.

Comparing REDEFINE 9’s approximately 21 percent efficacy-estimand weight loss with REDEFINE 1’s 22.7 percent remains tempting. But the trials enrolled different groups, used different designs and evaluated dosing under different conditions. REDEFINE 9 involved 309 randomized adults, compared with more than 3,400 in REDEFINE 1.

Most importantly, the studies did not directly randomize comparable participants within one trial to the 1.0 mg, 1.7 mg and 2.4 mg combinations. The apparent closeness of their weight-loss estimates cannot prove that all three doses are equally effective.

REDEFINE 9 therefore adds evidence about lower-dose efficacy without resolving whether a full-dose regimen offers additional benefit for some patients, how much that benefit might be, or how it changes adverse-event risk.

What it means and what to watch

For patients and clinicians, the possible implication is greater treatment flexibility. Different dose levels might eventually allow treatment to be individualized according to response, tolerability and clinical needs. But that possibility remains contingent on additional evidence and regulatory review.

The current findings do not mean patients should independently reduce prescribed doses of semaglutide or other medicines, or attempt to reproduce the investigational combination. CagriSema has not been approved by the FDA, and its safety and effectiveness have not been established for commercial clinical use.

The REDEFINE 9 findings were published online on November 14 and presented during ObesityWeek 2026 in Washington, D.C., which ran from November 14 through November 17. The trial adds a peer-reviewed data set to Novo Nordisk’s application-era evidence, although the U.S. submission currently under review concerns the 2.4 mg combination.

Novo continues to expect a regulatory decision during the fourth quarter of 2026. Approval of the full-dose product, if granted, would not automatically establish approved lower-dose treatment options. Any such dosing recommendations would depend on the evidence accepted by regulators and the resulting prescribing information.

Several scientific questions remain. Why were the estimated effects of 1.0 mg and 1.7 mg so close under the efficacy estimand? Would a head-to-head study against 2.4 mg reveal a clinically meaningful dose-response relationship? Which participants benefit from a higher dose, and which can achieve satisfactory outcomes with less medication? And could alternative titration schedules improve long-term adherence?

The peer-reviewed paper answers more than the September press release did. It provides the second dose result, study completion and treatment persistence figures, additional safety data, and an alternative set of weight-loss estimates that account for discontinuation.

What it does not establish is that less medication produces more weight loss. The more defensible conclusion is also the more useful one: two lower CagriSema doses produced substantial weight reductions in this controlled trial, and their results were close enough to justify further investigation of how much drug different patients actually need.

The next step is not to declare a winning dose. It is to test whether the apparent similarity persists in direct comparisons, whether tolerability meaningfully improves with less drug, and what those trade-offs mean for treatment over years rather than months.

Sources

  1. Wharton S, Broholm C, Horn D, et al. Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1.7 mg each and 1.0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial. The Lancet Diabetes & Endocrinology. Published online November 14, 2026. PubMed record.
  2. Novo Nordisk — Investigational CagriSema demonstrated approximately 21% average weight loss with lower doses in REDEFINE 9, November 14, 2026. Includes efficacy, treatment-regimen and safety results.
  3. Novo Nordisk — REDEFINE 9 publication presentation slides, ObesityWeek 2026. Contains study design, participant flow, weight-loss outcomes and adverse-event details.
  4. Novo Nordisk — REDEFINE 9 and REIMAGINE 5 topline results, September 21, 2026.
  5. Novo Nordisk — CagriSema demonstrates superior weight loss in REDEFINE 1, December 20, 2024.
  6. Novo Nordisk — CagriSema submitted to the US FDA for weight management, December 18, 2025.
  7. Reuters — Novo Nordisk must face US shareholder lawsuit over CagriSema weight loss trial, July 28, 2026.
  8. Grey Pepper — Novo Was Sued Over How CagriSema Was Dosed. Its Next Readout Tests Lower Doses., November 5, 2026.
  9. Grey Pepper — Petrelintide’s Amylin Bet Is About More Than Chasing the Biggest Weight-Loss Number, October 30, 2026.

Read more

Local News